1 / 25

Drug information: Ezetimibe

Drug information: Ezetimibe. 卒後研修センター  TTSP 薬剤研修生 杉田 栄樹. Dosage forms. Tablet: Zetia TM :10 mg (capsule shaped). Dosing. Adults (Elderly): Hyperlipidemias, Sitosterolemia: Oral 10 mg/day Renal impairment:

gales
Download Presentation

Drug information: Ezetimibe

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Drug information: Ezetimibe 卒後研修センター TTSP薬剤研修生 杉田 栄樹

  2. Dosage forms • Tablet: • ZetiaTM:10 mg (capsule shaped)

  3. Dosing • Adults (Elderly): • Hyperlipidemias, Sitosterolemia: Oral 10 mg/day • Renal impairment: • Bioavailability increased with severe impairment; no dosing adjustment recommended. • Hepatic impairment: • Bioavailability increased with severe impairment; • Mild impairment (Child-Pugh score 5-6) : No dosing adjustment necessary. • Moderate to severe impairment (Child-Pugh score 7-15) : Use of ezetimibe not recommended.

  4. Use • Use in combination with dietary therapy for the treatment of primary hypercholesterolemia (as monotherapy or in combination with HMG-CoA reductase inhibitors); homozygous sitosterolemia; homozygous familial hypercholesterolemia (in combination with atorvastatin or simvastatin); mixed hyperlipidemia (in combination with fenofibrate)

  5. CONTRAINDICATIONS • Hypersensitivity to any component of this medication.

  6. Administration • May be administered without regard to meals. May be taken at the same time as HMG-CoA reductase inhibitors. Administer 2 hours before or 4 hours after bile acid sequestrants.

  7. Mechanism of action • Localizes and appears to act at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. • Reduces total-C, LDL-C, Apo B, and TG, and increases HDL-C in patients with hypercholesterolemia.

  8. Pharmacodynamics/kinetics • Protein binding: >90% to plasma proteins • Metabolism: Undergoes conjugation in the small intestine and liver; forms metabolite (active); may undergo enterohepatic recycling • Bioavailability: Variable • Half-life: 22 hours (ezetimibe and metabolite) • Time to peak, plasma: 4-12 hours • Excretion: Feces (78%, 69% as ezetimibe); urine (11%, 9% as metabolite)

  9. Drug interaction • Cholestyramine: Bile Acid Seqestrants may decrease the absorption of Ezetimibe. • Cyclosporine: Cyclosporine may increase the serum concentration of Ezetimibe. Ezetimibe may increase the serum concentration of Cyclosporine.

  10. Adverse reactions • 1% to 10% • Cardiovascular: Chest pain (3%), dizziness (3%), fatigue (2%) • Central nervous system: Headache (8%) • Gastrointestinal: Diarrhea (3% to 4%), abdominal pain (3%) • Neuromuscular & skeletal: Arthralgia (4%) • Respiratory: Sinusitis (4% to 5%), pharyngitis (2% to 3%) • Postmarking and/or case reports • Anaphylaxis, cholecystitis, CPK increased, hepatitis, hypersensitivity reactions (including angioedema and rash), myaglia, myopathy, nausea, pancreatitis, rhabdomyolysis, thrombocytopenia, transaminases increased, urticaria

  11. Monitoring parameter • Total cholesterol profile prior to therapy, and when clinically indicated and/or periodically thereafter. When used in combination with fenofibrate, monitor LFTs and signs and symptoms of cholelithiasis.

  12. Ezetimibe/Simvastatin vs Atorvastatin in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia: The VYTAL Study 卒後研修センター TTSP薬剤研修生 杉田 栄樹

  13. Journal: Mayo clinic proceedings. • Published: December 2006. • Provided by Merck/Schering-Plough

  14. Background • High rates of CVD-related morbidity and mortality in this population are attributed in part to lipid abnormalities, typified by increased TG levels, HDL-C levels, and LDL-C. • Solano MP, et al. Management of dyslipidemia in diabetes. Cardiol Rev. 2006;14:125-135. • The challenge of attaining more stringent LDL-C targets has stimulated research into possible new combinations of lipid-lowering drugs. • Kennedy AG, et al. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care. 2005;28:1029-1034. • Ezetimibe has emerged as an effective agent for combined use with statins to achieve the recommended levels of LDL-C. • American Diabetes Association. Standard of medical care in diabetes-2006[published correction appears in Diabetes Care. 2006;29:1192]. Diabetes Care. 2006;14:125-135.

  15. Objective • To compare the efficacy and safety of the recommended usual starting and next highest doses with type 2 diabetes mellitus and hypercholesterolemia.

  16. Method • Design: Double-blind, multicenter study, RCT • Facility: 147 participating centers in US. • Patient: Type-2 diabetes patients (aged 18-80 years) with hemoglobin A1c levels of 8.5% or less. Patients who had an LDL-C level greater than 100mg/dL and a triglyceride level less than 400mg/dL in the third week of the run-in.

  17. Method • Treatment: • Administered daily for 6 weeks. • Starting doses: ezetimibe/simvastatin 10/20 mg/day, vs atorvastatin 10 or 20 mg/day • Next highest doses: ezetimibe/simvastatin 10/40 mg/day, vs atorvastatin 40 mg/day

  18. Assessment of Drug effect • Safety was assessed by monitoring clinical adverse events and laboratory adverse events. • Efficacy end points included percent changes from baseline in LDL-C levels (primary) and proportion of patients attaining LDL-C levels less than 70 mg/dL (secondary).

  19. Conclusion • Ezetimibe/simcastatin provided additional lipid-modifying benefits over atorvastatin monotherapy at the recommended usual starting and next highest doses in patients with type 2 diabetes. Both treatments were generally well tolerated.

  20. In my opinion • 治療効果を見るに当たっては、他のHMG-CoA阻害薬単独での最大治療効果は6週間後といわれているため、併用療法と単剤療法との比較には6週間の治療期間効果は妥当である。しかし、有害事象においては、投与開始の6週間以内であれば有害事象は少ないことがわかるが、治療期間が6週間と短いため、6週間以降に有害事象がないとはいいきれない。つまり、安全性を試験するのであれば、6週間以降の患者の状態もモニタリングする必要があると思われる。

More Related